Foghorn Therapeutics Income Statement (2019-2026) | FHTX

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.28M0.04M0.71M3.92M4.49M6.63M4.18M5.31M5.60M17.48M5.77M5.05M6.89M7.81M2.86M5.95M7.56M8.15M9.25M3.27M
Operating items
Research & Development (Quarter)
18.64M20.49M22.46M24.51M25.97M26.93M28.21M29.98M29.25M26.25M24.20M25.53M23.80M24.69M20.51M21.63M21.79M20.00M22.05M18.26M
Selling, General & Administrative (Quarter)
4.90M5.81M6.33M7.22M7.70M7.96M7.86M8.64M8.40M8.31M7.02M7.71M7.33M6.97M6.35M7.24M6.86M6.65M6.80M6.58M
Other Operating Expenses (Quarter)
2.40M4.28M
Operating Expenses (Quarter)
23.54M26.30M28.80M31.72M33.68M34.89M36.07M38.63M37.65M34.56M31.23M33.24M33.52M31.66M26.86M28.86M28.65M26.65M33.12M24.84M
Operating Income (Quarter)
-23.26M-26.26M-28.08M-27.80M-29.19M-28.26M-31.89M-33.32M-32.05M-17.08M-25.46M-28.19M-26.63M-23.85M-24.00M-22.91M-21.10M-18.50M-23.88M-21.57M
EBIT (Quarter)
-23.26M-26.26M-28.08M-27.80M-29.19M-28.26M-31.89M-33.32M-32.05M-17.08M-25.46M-28.19M-26.63M-23.85M-24.00M-22.91M-21.10M-18.50M-23.88M-21.57M
Non-operating items
Interest & Investment Income (Quarter)
0.23M1.23M1.84M2.38M2.67M2.79M2.75M2.66M2.44M2.87M3.50M3.10M2.69M2.31M2.03M1.71M1.74M
Other Non Operating Income (Quarter)
0.65M0.68M-1.20M0.66M0.65M0.65M0.62M0.72M0.71M0.72M0.68M0.74M0.78M1.24M1.41M1.39M0.85M0.62M0.50M-0.04M
Non Operating Income (Quarter)
0.15M0.18M-1.06M0.89M1.88M2.49M3.00M3.39M3.50M3.47M3.34M3.18M3.65M4.73M4.50M4.08M3.16M2.65M2.21M1.70M
Net income details
EBT (Quarter)
-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-29.93M-28.55M-13.61M-22.12M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M-22.17M-19.83M
Tax Provisions (Quarter)
0.56M0.94M0.74M1.99M
Profit After Tax (Quarter)
-23.11M-26.08M-29.14M-26.91M-27.31M-25.77M-28.90M-30.49M-29.49M-14.35M-24.13M-25.02M-22.98M-19.12M-19.48M-18.83M-17.94M-15.85M-21.68M-19.90M
Income from Continuing Operations (Quarter)
-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-30.49M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M-22.17M-19.83M
Consolidated Net Income (Quarter)
-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-30.49M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M-22.17M-19.83M
Income towards Parent Company (Quarter)
-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-30.49M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M-22.17M-19.83M
Net Income towards Common Stockholders (Quarter)
-23.76M-26.76M-28.51M-26.91M-27.31M-25.77M-28.89M-30.49M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-20.22M-18.79M-16.47M-22.17M-19.83M
Additional items
EPS (Basic) (Quarter)
-0.63-0.71-0.77-0.65-0.66-0.62-0.69-0.73-0.70-0.34-0.57-0.59-0.45-0.31-0.30-0.30-0.28-0.25-0.34-0.29
EPS (Weighted Average and Diluted) (Quarter)
-0.63-0.71-0.77-0.65-0.66-0.62-0.69-0.73-0.70-0.34-0.57-0.59-0.45-0.31-0.30-0.30-0.28-0.25-0.34-0.29
Shares Outstanding (Weighted Average) (Quarter)
36.85M36.88M37.17M41.37M41.52M41.67M41.59M41.81M41.82M42.03M41.97M42.43M47.00M62.60M54.90M62.85M62.98M62.95M62.98M69.54M
Shares Outstanding (Diluted Average) (Quarter)
36.83M36.88M37.17M41.37M41.52M41.67M41.59M41.81M41.82M42.03M41.97M42.43M51.58M62.60M54.90M62.85M62.91M63.03M62.98M69.54M
EBITDA (Quarter)
-23.13M-26.08M-29.12M-28.10M-29.31M-27.44M-28.01M-29.37M-29.34M-13.52M-23.04M-24.69M-22.82M-18.42M-19.73M-18.95M-17.99M-15.78M-21.66M-20.03M
Interest Expenses (Quarter)
0.49M0.50M0.43M
Tax Rate (Quarter)
-1.87%-3.30%-5.42%-8.98%